Gefitinib monotherapy in advanced nonsmall cell lung cancer: a large Western community implementation study.

@article{Puijenbroek2006GefitinibMI,
  title={Gefitinib monotherapy in advanced nonsmall cell lung cancer: a large Western community implementation study.},
  author={R van Puijenbroek and Lionel Bosqu{\'e}e and A. P. Meert and Denis C. C. Schallier and J. Goeminne and Guido Tits and Philippe Collard and Kristiaan Nackaerts and Julio Ca{\~n}{\'o}n and Fabrice Duplaquet and Danny Galdermans and Paul Germonpr{\'e} and M-A Azerad and Guy Vandenhoven and Jacques De Gr{\`e}ve and Johan Vansteenkiste},
  journal={The European respiratory journal},
  year={2006},
  volume={29 1},
  pages={
          128-33
        }
}
Epidermal growth factor receptor tyrosine kinase inhibitors represent a new treatment option for patients with advanced nonsmall cell lung cancer (NSCLC). This retrospective study examined to what extent previous clinical trial experience matches large-scale Western community implementation of this treatment. In the Belgian expanded access programme, the data from 513 patients with advanced or metastatic NSCLC, not suitable for further chemotherapy and receiving oral gefitinib 250 mg.day(-1… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 10 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 24 REFERENCES

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

  • GD Demetri, M Von Mehren, CD Blanke
  • N Engl J Med
  • 2005

Similar Papers

Loading similar papers…